Innate Pharma SA balance sheet

At the end of fiscal 2025, Innate Pharma SA had total assets of $73.6m and shareholders' equity of −$25.5m. It held $33.0m in cash against $0 of debt: net cash of $33.0m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Innate Pharma SA: balance sheet, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	119	174	228	167	117	90	78	69	33
Receivables	26	174	21	27	21	41	61	5	15
Total current assets	165	366	267	212	156	150	164	89	55
Total assets	307	517	451	376	303	213	194	115	74
Total current liabilities	89	225	137	56	90	44	44	34	43
Total debt	0	0	0	0	0	0	0	0	0
Shareholders' equity	120	191	244	191	122	58	57	9	−25
Net debt (negative = net cash)	−119	−174	−228	−167	−117	−90	−78	−69	−33
Shares outstanding	—	—	—	—	—	80m	—	—	—

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CRBU vs IPHA IPHA vs RLAY IPHA vs IRD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Innate Pharma SA's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Innate Pharma SA.